+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Liquid Biopsy Market by Product & Service, Cancer Type, Circulating Biomarker - Global Opportunity Analysis and Industry Forecast, 2017-2023

  • ID: 4612677
  • Report
  • Region: Global
  • 164 pages
  • Allied Analytics LLP
1 of 4
Liquid biopsies are non-invasive blood tests that detect tumor DNA & RNA fragments and circulating tumor cells (CTCs), which are released into the blood from the primary tumors and metastatic sites. It is a minimally invasive technology for the detection of molecular biomarkers, excluding expensive or invasive procedures. The global liquid biopsy market accounted for $634 million in 2016, and is estimated to reach at $3,805 million by 2023, registering a CAGR of 28.9% from 2017 to 2023.

Liquid biopsy is a simple and precise alternative to surgical biopsies, which allows physicians & surgeons to detect & treat cancer at an early stage and acquire tumor information through blood samples. These biopsies are particularly significant as they help the physician to understand the molecular changes and dynamics of cancer. Moreover, cancer recurrence is expected to be understood through well-timed liquid biopsies.

Surge in prevalence of cancer, advantages of liquid biopsy over solid tumor biopsy, rise in awareness about minimally invasive procedures, and favorable government initiatives supplement the market growth. However, alternatives to liquid biopsies and unclear reimbursement & regulation scenario impede the growth. Furthermore, increase in pre-screening programs for cancer detection provide lucrative opportunity for the market players.

The liquid biopsy market is segmented based on product & service, cancer type, circulating biomarker, end user, and geography. Based on product & service, it is divided into reagents, instruments, and services. On the basis cancer type, it is classified into lung cancer, breast cancer, colorectal cancer, prostate cancer, liver cancer, and other cancer. According to circulating biomarkers, it is categorized into circulating tumor cell, extracellular vesicle, circulating tumor DNA [ctDNA], and other biomarkers. On the basis of end user, it is classified into hospital & laboratory and government & research centers. Geographically, it is analyzed based on four regions, namely, North America, Europe, Asia-Pacific, and LAMEA.

KEY PLAYERS PROFILED

Biocept, Inc.
Qiagen
F. Hoffmann-La Roche AG
Bio-Rad Laboratories Inc.
Myriad Genetics
Janssen Diagnostics, LLC.
Trovagene Inc.
Guardant Health Inc.
GRAIL
MDX Health SA

KEY MARKET BENEFITS FOR STAKEHOLDERS

The study provides an in-depth analysis of the global liquid biopsy market and the current trends and future estimations to elucidate the imminent investment pockets.
The report presents quantitative analysis of the market from 2016 to 2023 to enable stakeholders to capitalize on the prevailing market opportunities.
Extensive analysis of the market based on cancer types assists to understand the trends in the industry.
Key market players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.

Liquid Biopsy Market Key Segments:

By Product & Service

Reagents
Instruments
Services

By Cancer Type

Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Liver Cancer
Other Cancers

By Circulating Biomarker

Circulating Tumor Cells
Extracellular Vesicles
Circulating Tumor DNA [CtDNA]
Other Biomarkers

By End User

Hospitals & Laboratories
Government & Academic Research Centers

By Geography

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Taiwan
Rest of Asia-Pacific
LAMEA
Brazil
Turkey
Saudi Arabia
South Africa
Rest of LAMEA

The other players in the value chain include (profiles not included in the report)

Fraunhofer-Gesellschaft
Horizon Discovery
Illumina, Inc.
Cynvenio
Diagnologix
Exosome Sciences
CyoTrack
Note: Product cover images may vary from those shown
2 of 4
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. TOP PLAYER POSITIONING, 2016
3.4. PORTERS FIVE FORCES ANALYSIS
3.5. REGULATIONS
3.6. MARKET DYNAMICS
3.6.1. Drivers
3.6.1.1. Increase in demand for safe and non-invasive procedures
3.6.1.2. Surge in prevalence of cancer worldwide.
3.6.1.3. Advantages of liquid biopsy tests
3.6.2. Restraints
3.6.2.1. Limitations associated with liquid biopsy testing
3.6.2.2. Lack of awareness in developing in underdeveloped regions
3.6.3. Opportunities
3.6.3.1. Rise in pre-screening programs for cancer detection using liquid biopsy
3.6.3.2. Untapped potential of emerging markets

CHAPTER 4 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. KITS & REAGENTS
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.3. PLATFORMS & INSTRUMENTS
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.4. SERVICES
4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

CHAPTER 5 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. CIRCULATING TUMOR CELL (CTC)
5.2.1. Market size and forecast
5.3. CIRCULATING TUMOR DNA (CTDNA)
5.3.1. Market size and forecast
5.4. EXTRACELLULAR VESICLES (EVS)
5.4.1. Market size and forecast
5.5. OTHER BIOMARKERS
5.5.1. Market size and forecast

CHAPTER 6 LIQUID BIOPSY MARKET, BY CANCER TYPE
6.1. OVERVIEW
6.1.1. Market Size and Forecast
6.2. LUNG CANCER
6.2.1. Market size and forecast
6.3. BREAST CANCER
6.3.1. Market size and forecast
6.4. COLORECTAL CANCER
6.4.1. Market size and forecast
6.5. PROSTATE CANCER
6.5.1. Market size and forecast
6.6. LIVER CANCER
6.6.1. Market size and forecast
6.7. OTHER CANCERS
6.7.1. Market size and forecast

CHAPTER 7 LIQUID BIOPSY MARKET, BY END USER
7.1. OVERVIEW
7.1.1. Market size and forecast
7.2. HOSPITAL AND LABORATORY
7.2.1. Market size and forecast
7.3. GOVERNMENT AND ACADEMIC RESEARCH CENTERS
7.3.1. Market size and forecast

CHAPTER 8 LIQUID BIOPSY MARKET, BY GEOGRAPHY
8.1. OVERVIEW
8.1.1. Market size and forecast
8.2. NORTH AMERICA
8.2.1. Key market trends
8.2.2. Key growth factors and opportunities
8.2.3. Market size and forecast
8.2.3.1. U.S. market size and forecast
8.2.3.2. Canada market size and forecast
8.2.3.3. Mexico market size and forecast
8.3. EUROPE
8.3.1. Key market trends
8.3.2. Key growth factors and opportunities
8.3.3. Market size and forecast
8.3.3.1. Germany market size and forecast
8.3.3.2. France market size and forecast
8.3.3.3. UK market size and forecast
8.3.3.4. Italy market size and forecast
8.3.3.5. Rest of Europe market size and forecast
8.4. ASIA-PACIFIC
8.4.1. Key market trends
8.4.2. Key growth factors and opportunities
8.4.3. Market size and forecast
8.4.3.1. Japan market size and forecast
8.4.3.2. China market size and forecast
8.4.3.3. Australia market size and forecast
8.4.3.4. India market size and forecast
8.4.3.5. South Korea market size and forecast
8.4.3.6. Taiwan market size and forecast
8.4.3.7. India market size and forecast
8.4.3.8. Rest of Asia-Pacific market size and forecast
8.5. LAMEA
8.5.1. Key market trends
8.5.2. Key growth factors and opportunities
8.5.3. Market size and forecast
8.5.3.1. Brazil market size and forecast
8.5.3.2. Turkey market size and forecast
8.5.3.3. Saudi Arabia market size and forecast
8.5.3.4. South Africa market size and forecast
8.5.3.5. Rest of LAMEA market size and forecast

CHAPTER 9 COMPANY PROFILES
9.1. BIOCEPT, INC.
9.1.1. Company overview
9.1.2. Company snapshot
9.1.3. Operating business segments
9.1.4. Product portfolio
9.1.5. Business performance
9.2. QIAGEN N.V.
9.2.1. Company overview
9.2.2. Company snapshot
9.2.3. Operating business segments
9.2.4. Product portfolio
9.2.5. Business performance
9.3. F. HOFFMANN-LA ROCHE AG
9.3.1. Company overview
9.3.2. Company snapshot
9.3.3. Operating business segments
9.3.4. Product portfolio
9.3.5. Business performance
9.4. BIO-RAD LABORATORIES INC.
9.4.1. Company overview
9.4.2. Company snapshot
9.4.3. Operating business segments
9.4.4. Product portfolio
9.4.5. Business performance
9.5. MYRIAD GENETICS
9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Operating business segments
9.5.4. Product portfolio
9.5.5. Business performance
9.6. JANSSEN DIAGNOSTICS, LLC.
9.6.1. Company overview
9.6.2. Company snapshot
9.6.3. Operating business segments
9.6.4. Product portfolio
9.6.5. Business performance
9.7. TROVAGENE INC.
9.7.1. Company overview
9.7.2. Company snapshot
9.7.3. Operating business segments
9.7.4. Product portfolio
9.7.5. Business performance
9.8. GUARDIANT HEALTH, INC.
9.8.1. Company overview
9.8.2. Company snapshot
9.8.3. Operating business segments
9.8.4. Product portfolio
9.8.5. Business performance
9.9. GRAIL
9.9.1. Company overview
9.9.2. Company snapshot
9.9.3. Operating business segments
9.9.4. Product portfolio
9.9.5. Business performance
9.10. MDX HEALTH SA
9.10.1. Company overview
9.10.2. Company snapshot
9.10.3. Operating business segments
9.10.4. Product portfolio
9.10.5. Business performance
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Liquid Biopsy Market Report, forecasts that the global market accounted for $634 million in 2016, and is estimated to reach at $3,805 million by 2023, registering a CAGR of 28.9% from 2017 to 2023. North America was the highest contributor in the liquid biopsy market in 2016; however, Asia-Pacific is anticipated to witness a highest growth rate throughout the forecast period.

Liquid biopsy tests prove to be an easy and non-invasive method to access to molecular information about the tumor genome. Moreover, these tests facilitate early detection of cancer recurrence and characterization of tumor dymics. Safety and efficiency of cancer treatment is improved by the use of these tests, owing to their ability to characterize new lesions, implement apt therapeutic targets, and predict the treatment outcome.

The advantages of implementing liquid biopsy over conventiol methods of solid tissue biopsy are expected to boost the growth of the market. The advantages of liquid biopsies, such as minimally invasiveness and metastatic relapse evaluation, are expected to increase the demand for these tests. Furthermore, the increase in disposable income among cancer patients, surge in prevalence of cancer cases, and patient preference for minimally invasive therapies are anticipated to fuel the market growth. Rise in healthcare expenditure in the developing countries, such as India and Chi, and use of liquid biopsy tests to treat rare cancers are expected to present multiple opportunities for market growth. However, this growth is restricted, owing to altertives to liquid biopsies and unclear reimbursement & regulation scerio.

Reagent was the highest revenue contributor in 2016, and is anticipated to continue this trend in the future. The requirement of reagents to execute liquid biopsy tests and their applicability are expected to boost the growth of this segment.

Lung cancer domites the cancer by type segment of liquid biopsy market. The U.S. Food and Drug Administration (FDA) has also approved a liquid biopsy companion diagnostic test called cobas EGFR mutation test v2 to identify patients with metastatic non-small cell lung cancer (NSCLC) In addition, the growth in prevalence of lung cancer has contributed to provide lucrative opportunities in the market.

In 2016, North America accounted for highest contribution to the total revenue generated, owing to the high prevalence rate of cancer and high adoption rate of novel liquid biopsy tests. However, Asia-Pacific is expected to witness the highest CAGR during the alysis period, attributable to rise in disposable income, increase in government initiatives to modernize healthcare infrastructure, and rise in healthcare expenditure.

Key findings of the Liquid Biopsy Market:

The government & academic research center segment is projected to grow at the highest rate during the alysis period.
Hospital & laboratory segment was the highest revenue-generating segment, and is expected to continue its domince in future.
North America domited global liquid biopsy market, and is projected to grow at a CAGR of 28.1%.
Chi is expected to grow at the highest CAGR of 34.1% in Asia-Pacific region.
The instruments segment is anticipated to grow at the highest CAGR of 29.8% during the forecast period.

The key companies profiled in the report include Biocept, Inc., Qiagen, F. Hoffmann-La Roche AG , Bio-Rad Laboratories Inc., Myriad Genetics , Janssen Diagnostics, LLC., Trovagene Inc., Guardant Health Inc., GRAIL, and MDX Health SA.
Note: Product cover images may vary from those shown
5 of 4

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Order Online - visit: https://www.researchandmarkets.com/reports/4612677
Adroll
adroll